Cannabinoid Therapy in Female Pelvic Medicine and Reconstructive Surgery: Current Evidence and Future Directions

Jocelyn Stairs; Finlay Maguire; Christian Lehmann; Ashley Cox

doi:10.1007/s11884-021-00632-5

Cannabinoid Therapy in Female Pelvic Medicine and Reconstructive Surgery: Current Evidence and Future Directions

Jocelyn Stairs, Finlay Maguire, Christian Lehmann, Ashley Cox

Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Purpose of Review: In this review, we examine the current literature regarding the use of cannabinoids in several areas of female pelvic medicine and reconstructive surgery (FPMRS) including overactive bladder, interstitial cystitis/bladder pain syndrome, and chronic pelvic pain. Recent Findings: Animal models support the role of the endocannabinoid system in the pathophysiology of these disorders and several drug targets have been identified. However, clinical studies remain limited. Palmitoylethanolamine (PEA) is emerging as a possible therapy for pain in this context. Summary: There is currently insufficient evidence to support cannabinoid therapy in disorders related to FPMRS and many of the clinical studies to date have limitations in terms of size and study design.

Original language	English
Pages (from-to)	64-73
Number of pages	10
Journal	Current Bladder Dysfunction Reports
Volume	16
Issue number	3
DOIs	https://doi.org/10.1007/s11884-021-00632-5
Publication status	Published - Sept 2021

Bibliographical note

Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

ASJC Scopus Subject Areas

Biochemistry
Molecular Biology

Access to Document

10.1007/s11884-021-00632-5

Cite this

@article{71579826b03648698792714fc71350c8,

title = "Cannabinoid Therapy in Female Pelvic Medicine and Reconstructive Surgery: Current Evidence and Future Directions",

abstract = "Purpose of Review: In this review, we examine the current literature regarding the use of cannabinoids in several areas of female pelvic medicine and reconstructive surgery (FPMRS) including overactive bladder, interstitial cystitis/bladder pain syndrome, and chronic pelvic pain. Recent Findings: Animal models support the role of the endocannabinoid system in the pathophysiology of these disorders and several drug targets have been identified. However, clinical studies remain limited. Palmitoylethanolamine (PEA) is emerging as a possible therapy for pain in this context. Summary: There is currently insufficient evidence to support cannabinoid therapy in disorders related to FPMRS and many of the clinical studies to date have limitations in terms of size and study design.",

author = "Jocelyn Stairs and Finlay Maguire and Christian Lehmann and Ashley Cox",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2021",

month = sep,

doi = "10.1007/s11884-021-00632-5",

language = "English",

volume = "16",

pages = "64--73",

journal = "Current Bladder Dysfunction Reports",

issn = "1931-7212",

publisher = "Current Medicine Group",

number = "3",

}

TY - JOUR

T1 - Cannabinoid Therapy in Female Pelvic Medicine and Reconstructive Surgery

T2 - Current Evidence and Future Directions

AU - Stairs, Jocelyn

AU - Maguire, Finlay

AU - Lehmann, Christian

AU - Cox, Ashley

PY - 2021/9

Y1 - 2021/9

N2 - Purpose of Review: In this review, we examine the current literature regarding the use of cannabinoids in several areas of female pelvic medicine and reconstructive surgery (FPMRS) including overactive bladder, interstitial cystitis/bladder pain syndrome, and chronic pelvic pain. Recent Findings: Animal models support the role of the endocannabinoid system in the pathophysiology of these disorders and several drug targets have been identified. However, clinical studies remain limited. Palmitoylethanolamine (PEA) is emerging as a possible therapy for pain in this context. Summary: There is currently insufficient evidence to support cannabinoid therapy in disorders related to FPMRS and many of the clinical studies to date have limitations in terms of size and study design.

AB - Purpose of Review: In this review, we examine the current literature regarding the use of cannabinoids in several areas of female pelvic medicine and reconstructive surgery (FPMRS) including overactive bladder, interstitial cystitis/bladder pain syndrome, and chronic pelvic pain. Recent Findings: Animal models support the role of the endocannabinoid system in the pathophysiology of these disorders and several drug targets have been identified. However, clinical studies remain limited. Palmitoylethanolamine (PEA) is emerging as a possible therapy for pain in this context. Summary: There is currently insufficient evidence to support cannabinoid therapy in disorders related to FPMRS and many of the clinical studies to date have limitations in terms of size and study design.

UR - http://www.scopus.com/inward/record.url?scp=85107315532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107315532&partnerID=8YFLogxK

U2 - 10.1007/s11884-021-00632-5

DO - 10.1007/s11884-021-00632-5

M3 - Review article

AN - SCOPUS:85107315532

SN - 1931-7212

VL - 16

SP - 64

EP - 73

JO - Current Bladder Dysfunction Reports

JF - Current Bladder Dysfunction Reports

IS - 3

ER -

Cannabinoid Therapy in Female Pelvic Medicine and Reconstructive Surgery: Current Evidence and Future Directions

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this